Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08YHB
|
|||
| Former ID |
DNCL001645
|
|||
| Drug Name |
BIIB 023
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1] | |
| Company |
Biogen Idec
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TNF-related weak inducer of apoptosis (TWEAK) | Target Info | Modulator | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01930890) BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT00771329) BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | |||
| REF 3 | A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs. 2014 January 1; 6(1): 297-308. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.